A Novel Prognostic Ferroptosis-Related Long Noncoding RNA Signature in Clear Cell Renal Cell Carcinoma

Figure 12

Estimation of the tumor immunotherapy response (IC50) using the FRLRS model in KIRC: (a) drugSenstivity.A.443654; (b) drugSenstivity.A.770041; (c) drugSenstivity.ABT.888; (d) drugSenstivity.AG.014699; (e) drugSenstivity.AKT.inhibitor.VIII; (f) drugSenstivity.AMG.706; (g) drugSenstivity.AP.24534; (h) drugSenstivity.AS601245; (i) drugSenstivity.AZ628; (j) drugSenstivity.AZD.0530; (k) TIDE in two risk groups of ccRCC patients.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)